Company: LIMN
Filing Date: 2025-01-27
Form Type: POS AM
Source: 0001104659-25-006325
Chunk: 406

Company: Liminatus Pharma, Inc.
Filing Date: 2025-01-27
Form: POS AM
Chunk 406
---
ory note is compounded annually, and accrues on each unpaid advance made under the promissory note at the rate of 5% per annum.

#### Underwriting Agreement
On October 11, 2023, the Company executed a Fee Reduction Agreement with the underwriters to reduce the deferred underwriting discount of $9,660,000 to $8,000,000, of which $7,000,000 will be paid in ParentCo Common Stock (700,000 shares at $10.00 per share) upon the completion of Iris’s initial business combination. The share price is subject to adjustment based on the five day volume-weighted average price prior to the filing of a resale registration statement covering such shares.

#### Ancillary Agreements
In connection with the consummation of the Business Combination, ParentCo will enter into a Lock-Up Agreement, Sponsor Support Agreement, Sponsor Forfeiture Agreement, Amended and Restated Registration Rights Agreement and Warrant Amendment (together the “Ancillary Agreements”) with certain parties, including the Sponsor as contemplated by the Business Combination. See “ Proposal No. 1 — The Business Combination Proposal — Additional Agreements Executed at the Signing of the Business Combination ” for a description of these agreements.

<div align='center'>224</div>

TABLE OF CONTENTS

### INFORMATION ON SECURITIES AND DIVIDENDS

#### Iris

#### Market Information
Iris’s Class A Common Stock and Iris Public Warrants are currently traded on the OTC Pink Marketplace under the symbols “IRAA” and “IRAAW,” respectively. Certain shares of Iris Class A Common Stock and Iris Public Warrants currently trade as Iris Units consisting of one share of Iris Class A Common Stock and one-fourth of one redeemable warrant, and are traded on the OTC Pink Marketplace under the symbol “IRAAU” The Iris Units will automatically separate into their component securities upon consummation of the Business Combination and those component securities will be converted into ParentCo securities and, as a result, Iris Class A Common Stock, Iris Units and Iris warrants will no longer trade as independent securities. ParentCo intends for ParentCo Common Stock and ParentCo Public Warrants to be listed on the Nasdaq Global Market under the market value standard, under the symbols “LIMN” and “LIMNW,” respectively, upon the consummation of the Business Combination. At the Effective Time, we expect ParentCo will satisfy all of the initial listing requirements under the market value standard; however, we